Skip to main content
Clinical Trials/CTRI/2025/11/097261
CTRI/2025/11/097261Not yet recruitingNot Applicable

TO ASSESS TO UTEROSTONIC EFFECTS OF CARBETOCIN VERSUS OXYTOCIN IN A CESAREAN SECTION WITH A HIGH RISK OF POST PARTUM HEMORRHAGE

DR GAURI GOYAL1 site in 1 country188 target enrollmentStarted: February 2, 2026Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
188
Locations
1
Primary Endpoint
Uterotonic effect: post partum hemorrheage rate (i.e. number of women who experience postpartunm hemorrhage even after drug administration ) after drug administration

Study Overview

Brief Summary

a prospective comparative observational study To Assess The Uterotonic Effects Of  Carbetocin Versus Oxytocin In A Cesarean Section With A High Risk Of Postpartum Hemorrhage in 188 patients. participants will be consecutively allocated into two groups based on the uterotonic agent received: Group A(UNIT IIIA- UNDER DR NAMITA DOHAREY) will consist of women who will be administered 100 µg of intravenous carbetocin as a single bolus at the delivery of the anterior shoulder, while Group B(UNIT IIIB- UNDER DR VISHI) will include women who will receive 20 IU of oxytocin diluted in 1000 mL of 0.9% sodium chloride solution, infused at a rate of 150 mL per hour starting at the same time point. primary outcome will be to measure  post partum hemorrheage rate (i.e. number of women who experience postpartunm hemorrhage even after drug administration ) after drug administration and secondary outcomes will be Hemodynamic Effects: Changes in systolic and diastolic blood pressure at: Baseline (after CSE anesthesia), 1, 3, and 5, 10 and 60 minutes after drug administration, Estimated Blood Loss: Intraoperative and immediate postoperative blood loss estimation,  Need for Additional Uterotonics: Proportion of women requiring additional uterotonic agents (e.g., methylergometrine, misoprost, carboprost), Hemoglobin Drop: Change in hemoglobin levels: Preoperative, 2 hours postoperative, 24 hours postoperative and Adverse Effects: Incidence of Postop Nausea and Vomiting, Flushing, Headache, Dyspnea

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18.00 Year(s) to 45.00 Year(s) (—)
Sex
Female

Inclusion Criteria

  • •Women scheduled for cesarean section who are willing to participate.
  • •Presence of maternal risk factors for PPH, such as: 1- Multifetal pregnancy 2- Previous cesarean section 3- Elderly gravida 4- Multiparpus female 5-Uterine fibroids, myomectomy history, or placenta previa, placenta accreta spectrum 6-Past history of postpartum hemorrhage 7-Presence of fetal risk factors, including macrosomia or polyhydramnios-associated malformations.(related with uterine overdistension) 8-IVF conceived pregnancy •Hypertension or preeclampsia.

Exclusion Criteria

  • Women giving negative consent to participate in study •women with Cardiac, renal, or hepatic disease •Epilepsy •Hypersensitivity to carbetocin (as per British National Formulary) •Undergo general anesthesia for the cesarean section.

Outcomes

Primary Outcomes

Uterotonic effect: post partum hemorrheage rate (i.e. number of women who experience postpartunm hemorrhage even after drug administration ) after drug administration

Time Frame: Uterotonic effect: post partum hemorrheage rate (i.e. number of women who experience postpartunm hemorrhage even after drug administration ) after drug administration

Secondary Outcomes

  • 1. Hemodynamic Effects: Changes in systolic & diastolic blood pressure at: Baseline (after CSE anesthesia), 1, 3, & 5, 10 & 60 minutes after drug administration,
  • estimated Blood Loss: Intraoperative & immediate postoperative blood loss estimation
  • Need for Additional Uterotonics: Proportion of women requiring additional uterotonic agents (e.g., methylergometrine, misoprost, carboprost)
  • Hemoglobin Drop: Change in hemoglobin levels: Preoperative, 2 hours postoperative, 24 hours postoperative
  • Adverse Effects: Incidence of Postop Nausea and Vomiting, Flushing, Headache, Dyspnea

Investigators

Sponsor
DR GAURI GOYAL
Sponsor Class
Other [self]
Responsible Party
Principal Investigator
Principal Investigator

DR GAURI GOYAL

DR RAM MANOHAR LOHIA INSTITUTE OF MEDICAL SCIENCES

Study Sites (1)

Loading locations...

Similar Trials